【打印本页】 【下载PDF全文】 【HTML】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 1788次   下载 1622 本文二维码信息
码上扫一扫!
Ras相关区域家族10蛋白在胃癌中的表达及其临床意义
张宇,卫子然,杨德君,王长明,颜荣林*
0
(第二军医大学长征医院胃肠外科, 上海 200003
共同第一作者
*通信作者)
摘要:
目的 探讨Ras相关区域家族10(Ras-association domain family 10,RASSF10)蛋白在人类胃癌中的表达及其与胃癌患者预后相关的临床病理学参数的关系。方法 选取2008年1月至2010年12月在第二军医大学长征医院手术切除的胃癌标本共105例。所有患者临床病理学资料详实,至少随访5年或随访至死亡。应用免疫组织化学方法检测胃癌组织中RASSF10的表达,并分析其与临床病理学参数和预后的关系。结果 免疫组化结果提示RASSF10在105例胃癌组织中阴性表达率为61.9%(65/105)。RASSF10表达水平与肿瘤大小、病理学分级、病理类型、T分期、淋巴结转移有关(P均<0.05),而与患者年龄、性别、肿瘤部位、远处转移、AJCC分期等无关(P>0.05)。Kaplan-Meier分析显示RASSF10表达阴性患者有着更差的预后(P<0.05)。Cox比例风险回归模型分析显示RASSF10表达(HR=0.528, P=0.041)和AJCC临床分期(HR=4.994, P=0.001)可作为胃癌患者的独立预后因子。结论 RASSF10蛋白在胃癌组织中表达下调,且与胃癌患者不良预后相关,提示其可能成为判断胃癌预后的潜在生物标记物。
关键词:  RASSF10  胃肿瘤  免疫组织化学  预后
DOI:10.16781/j.0258-879x.2016.05.0590
投稿时间:2015-12-27修订日期:2016-01-27
基金项目:上海市卫生与计划生育委员会科研课题(2014176).
Expression and clinical significance of Ras-association domain family 10 in gastric cancer
ZHANG Yu,WEI Zi-ran,YANG De-jun,WANG Chang-ming,YAN Rong-lin*
(Department of Gastrointestinal Surgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
Co-first authors
*Corresponding author)
Abstract:
Objective To examine the protein expression of Ras-association domain family 10 (RASSF10) in human gastric cancer and its association with clinicopathological parameters of prognosis in patients with gastric cancer. Methods A total of 105 gastric cancer specimens were collected in Changzheng Hospital, Second Military Medical University from Jan. 2008 to Dec. 2010. All patients had detailed clinicopathological data and were followed up for at least 5 years or till they were dead. Immunohistochemical (IHC) analysis was performed to detect RASSF10 expression in gastric carcinoma and adjacent normal tissues. The correlations between RASSF10 expression and clinicopathological factors, and patients' prognosis were evaluated through statistical analysis. Results The IHC results revealed that negative expression of RASSF10 was observed in 61.9% (65/105) of gastric cancer patients. The level of RASSF10 was significantly associated with the tumor size, pathological grade, pathological type, T stage and lymph node metastasis (all P<0.05), but not correlated with age, gender, tumor site, distant metastasis or AJCC staging (all P>0.05). Kaplan-Meier curve showed that negative expression of RASSF10 predicted significantly worsened prognosis of gastric cancer (P<0.05). Multivariate Cox regression analysis indicated that RASSF10 expression (HR=0.528, P=0.041) and AJCC stage (HR=4.994, P=0.001) were independent prognostic factors for the survival of gastric cancer patients. Conclusion RASSF10 protein is down-regulated in gastric cancer tissues and is associated with a poor prognosis of gastric cancer, which indicates that RASSF10 may serve as a potential prognostic biomarker for gastric cancer.
Key words:  RASSF10  stomach neoplasms  immunohistochemistry  prognosis